Colon cancer treatment almost always starts with surgery to remove the tumor, and the overall plan depends on how far the cancer has spread. Early-stage colon cancer caught in a polyp may need nothing more than a single procedure during a colonoscopy, while advanced cases typically involve some combination of surgery, chemotherapy, targeted therapy, or immunotherapy. The five-year survival rate for colon cancer caught before it spreads beyond the colon wall is 91.3%, which drops to 75.2% when nearby lymph nodes are involved and 16.9% when the cancer has reached distant organs.
Treatment by Stage
Stage 0 and Stage I colon cancers are the most straightforward to treat. If the cancer is contained within a polyp and the polyp is removed completely with clean margins during a colonoscopy, that may be the only treatment needed. For larger Stage 0 cancers or Stage I cancers not confined to a polyp, a partial colectomy (removing the section of colon containing the cancer along with nearby lymph nodes) is the standard approach.
Stage II cancer has grown through the colon wall but hasn’t reached the lymph nodes. Surgery is still the primary treatment, and chemotherapy afterward is generally reserved for cases with higher-risk features. Stage III means the cancer has spread to nearby lymph nodes, and the standard treatment is surgery followed by chemotherapy, typically lasting three to six months.
Stage IV colon cancer has spread to distant organs, most commonly the liver or lungs. Treatment here focuses on controlling the disease and extending life. Chemotherapy, targeted therapies, and immunotherapy all play a role. If the metastases are small and limited enough, surgery to remove both the primary tumor and the metastatic spots can sometimes be curative. When surgery isn’t an option, treatment aims to shrink or stabilize the cancer and relieve symptoms like bowel obstruction.
Surgery: What to Expect
The most common surgery for colon cancer is a partial colectomy, also called a colon resection. The surgeon removes the segment of colon containing the cancer along with a margin of healthy tissue on each side and the associated lymph nodes. The two healthy ends are then reconnected so the digestive tract functions normally. Depending on where the tumor sits, this might be called a right hemicolectomy, left hemicolectomy, or sigmoid colectomy.
In some cases, the healthy ends of the colon can’t be immediately reconnected. This happens when the area needs time to heal, when there’s a bowel obstruction, or when the surgery is more extensive than expected. The surgeon will then create a colostomy or ileostomy, routing the intestine to an opening in the abdomen so waste can drain into an external bag. This is often temporary, with a second procedure to reconnect the bowel once healing is complete, though in a minority of cases it becomes permanent.
For very early cancers found in polyps, a polypectomy during a routine colonoscopy may be sufficient. No abdominal incision is needed, and recovery is minimal. A total colectomy, removing the entire colon, is uncommon and typically reserved for people with underlying genetic conditions like Lynch syndrome or familial adenomatous polyposis that put them at high risk for additional cancers.
Chemotherapy After Surgery
Adjuvant chemotherapy, given after surgery to kill any remaining cancer cells, is standard for Stage III colon cancer and selectively used in high-risk Stage II cases. The two main regimens combine a platinum-based drug (oxaliplatin) with another chemotherapy agent. One regimen is given intravenously every two weeks, and the other pairs intravenous oxaliplatin with an oral chemotherapy pill taken at home.
The traditional course lasts six months, but a major international analysis of over 12,000 Stage III patients found that for people with lower-risk disease (about 60% of Stage III cases), three months of treatment delivered nearly identical results: 83.1% of patients remained cancer-free at three years compared to 83.3% in the six-month group. The shorter course also caused significantly less nerve damage. For higher-risk Stage III patients, six months still offers a meaningful benefit.
The most notable long-term side effect of these regimens is peripheral neuropathy, a tingling or numbness in the fingers and toes caused by oxaliplatin. For some people this fades after treatment ends, but others deal with it for months or years. Other common side effects during treatment include fatigue, nausea, and diarrhea.
Targeted Therapy and Biomarker Testing
Targeted therapies work differently from traditional chemotherapy. Instead of killing all rapidly dividing cells, they block specific molecules that help cancer cells grow and spread. Two main categories are used in colon cancer treatment.
The first targets a protein called VEGF, which tumors use to build new blood vessels and feed their growth. Drugs that block VEGF essentially starve the tumor of its blood supply and are often combined with chemotherapy in advanced colon cancer.
The second targets EGFR, a protein on the surface of cells that signals them to grow. These drugs only work in tumors with a “wild-type” (normal, non-mutated) version of the KRAS and NRAS genes. Mutations in KRAS or BRAF predict that EGFR-targeted treatments won’t be effective, which is why biomarker testing on the tumor tissue is a critical step before choosing a treatment plan. About 40% of colorectal cancers carry KRAS mutations, making them ineligible for this approach.
For the roughly 8 to 10% of metastatic colorectal cancers with a specific BRAF mutation (V600E), a targeted combination has shown striking results. Recent Phase III trial data presented in 2025 showed that combining a BRAF inhibitor with an EGFR blocker and standard chemotherapy cut the risk of death by 51% compared to chemotherapy alone.
Immunotherapy for Specific Tumor Types
Immunotherapy helps the immune system recognize and attack cancer cells, but it only works well in a specific subset of colon cancers. About 5% of people with advanced colorectal cancer have tumors classified as MSI-H or dMMR, meaning those tumors are unable to properly repair certain types of DNA damage during cell division. This defect actually makes the cancer more visible to the immune system, and immunotherapy drugs called checkpoint inhibitors can unleash a powerful immune response against it.
Multiple checkpoint inhibitor options are now approved as first-line treatment for advanced MSI-H or dMMR colorectal cancer, either as single agents or in combination. Recent trial results have reinforced this approach: adding a checkpoint inhibitor to standard chemotherapy after surgery in Stage III patients with dMMR tumors cut the risk of cancer recurrence in half compared to chemotherapy alone. For the small percentage of patients whose tumors have this feature, immunotherapy has fundamentally changed the treatment landscape.
When Radiation Is Used
Radiation is far more common in rectal cancer than in colon cancer, but there are situations where it plays a role. If the tumor has attached to an internal organ or the lining of the abdomen and the surgeon isn’t confident all the cancer was removed, radiation can target any cells left behind. It’s also used when a person isn’t healthy enough for surgery, or to relieve symptoms like pain, bleeding, or bowel obstruction from advanced disease. Colon cancer that has spread to the bones, lungs, or brain may also be treated with targeted radiation to those specific sites.
Recovery and Follow-Up
Recovery after colon surgery varies, but most people spend several days in the hospital and need four to six weeks before returning to normal activities. Bowel habits often change in the weeks and months following surgery. Chronic diarrhea, more frequent bowel movements, and difficulty holding stool are among the most common long-lasting effects, though many people see gradual improvement over time.
Follow-up care after treatment is structured and ongoing. For the first two years, most people have physical exams and blood tests every three to six months, then every six months for the next few years. A colonoscopy is typically done about one year after surgery. If that looks normal, the next one is usually three years later, and after that, every five years. Some side effects of treatment don’t appear until months after the last dose, which is one reason this monitoring schedule stretches out over years.
People treated for early-stage cancers generally follow a less intensive schedule, while those treated for advanced disease may need imaging scans at regular intervals to watch for recurrence. The pattern of follow-up your care team recommends will reflect both the original stage of the cancer and how it responded to treatment.